DB
TPST icon

Dmitry Balyasny’s Tempest Therapeutics TPST Stock Holding History

Dmitry Balyasny’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3
Closed -$98K – 1528
2015
Q4 		$98K Buy
+3
New +$98.9K ﹤0.01% 1165

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Dmitry Balyasny's TPST Position: Q1 2016 in Review

Dmitry Balyasny sold out of Tempest Therapeutics (TPST) in Q1 2016, closing a stake of 3 shares — an estimated $98K sold.

Dmitry Balyasny first reported a position in TPST in Q4 2015 and held it in 1 quarter. The position peaked at $98K in Q4 2015. 73 funds tracked by Wall St. Rank hold TPST as of Q1 2016.

  • Dmitry Balyasny reported no remaining Tempest Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Dmitry Balyasny sold 3 Tempest Therapeutics shares in Q1 2016, an estimated $98K.
  • Dmitry Balyasny first reported a position in Tempest Therapeutics in Q4 2015 and held it in 1 quarter.
  • Dmitry Balyasny's Tempest Therapeutics position peaked at $98K in Q4 2015.
  • 73 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2016.

Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.